BioClinica snags a Pfizer exec to take the helm

BioClinica, fresh from its latest merger, has named a Pfizer ($PFE) executive as its next CEO. John Hubbard, who served as senior vice president and worldwide head of development operations at Pfizer, will take the reins on Jan. 5, when longtime chief Mark Weinstein will step down. Hubbard oversaw more than 450 clinical projects in his time at Pfizer, BioClinica said, and his CV includes stops at Icon ($ICLR), Parexel ($PRXL) and Hoechst Marion Roussel Pharmaceuticals, since acquired by Sanofi ($SNY). More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.